Publikation

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer

Wissenschaftlicher Artikel/Review - 08.09.2014